103514-54-1

Basic information

• Product Name: Ethyl 4-chloro-6-nitroquinoline-3-carboxylate
• Synonyms: Ethyl 4-chloro-6-nitroquinoline-3-carboxylate
• CAS NO: 103514-54-1
• Molecular Weight: 280.66386
• Mol File: 103514-54-1.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: Ethyl 4-chloro-6-nitroquinoline-3-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl 4-chloro-6-nitroquinoline-3-carboxylate(103514-54-1)
• EPA Substance Registry System: Ethyl 4-chloro-6-nitroquinoline-3-carboxylate(103514-54-1)

Safety Data

• Hazardous Substances Data: 103514-54-1(Hazardous Substances Data)

Usage

General Description

Ethyl 4-chloro-6-nitroquinoline-3-carboxylate is a chemical compound that belongs to the class of quinoline derivatives. It is a yellow solid with the molecular formula C13H9ClN2O4 and a molecular weight of 288.67 g/mol. Ethyl 4-chloro-6-nitroquinoline-3-carboxylate is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. It possesses a nitro group and a chloro group, making it suitable for various chemical reactions and synthetic transformations. Due to its unique structure and reactivity, ethyl 4-chloro-6-nitroquinoline-3-carboxylate has potential applications in medicinal chemistry and materials science for the development of new drugs and advanced materials.

Upstream product

• 103514-53-0 6-nitro-4-hydroxy-quinoline-3-carboxylic acid ethylester 
• 78596-42-6 ethyl α-ethoxycarbonyl-β-(4-nitroanilino)acrylate 
• 100-01-6 4-nitro-aniline 
• 87-13-8 diethyl 2-ethoxymethylenemalonate 
• 103514-53-0 ethyl 6-nitro-4-oxo-1,4-dihydroquinoline-3-carboxylate 

Relevant articles and documents

Synthesis and anticancer activities of some novel 2-(benzo[d]thiazol-2-yl)- 8-substituted-2H-pyrazolo[4,3-c]quinolin-3(5H)-ones

A series of 2-(benzo[d]thiazol-2-yl)-8-substituted-2H-pyrazolo[4,3-c] quinolin-3(5H)-ones (3a-g) have been synthesized and evaluated for their in vitro antiproliferative activities against four human cancer cell lines: MDA-MB-435 (breast), HL-60 (leukemia), HCT-8 (colon) and SF-295 (central nervous system). The results showed that the compounds 3b (2-(benzo[d]thiazol-2-yl)-8- methyl-2H-pyrazolo[4,3-c]quinolin-3(5H)-one) and 3c (2-(benzo[d]thiazol-2-yl)-8- bromo-2H-pyrazolo[4,3-c]quinolin-3(5H)-one) exhibited good cytotoxicity for three cell lines with IC50 values lower than 5 μg/mL. Analysis of theoretical toxicity risks have shown medium tumorigenic and irritant risks related to 3b and 3c in contrast to doxorubicin, the positive control.